% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Sigaud:277810,
author = {R. Sigaud$^*$ and T. K. Albert and C. Hess$^*$ and T.
Hielscher$^*$ and N. Winkler$^*$ and D. Kocher$^*$ and C.
Walter and D. Münter and F. Selt$^*$ and D. Usta$^*$ and J.
Ecker$^*$ and A. Brentrup and M. Hasselblatt and C. Thomas
and J. Varghese and D. Capper and U. W. Thomale and P.
Hernáiz Driever and M. Simon and S. Horn and N. A. Herz and
A. Koch and F. Sahm$^*$ and S. Hamelmann$^*$ and A.
Faria-Andrade and N. Jabado and M. U. Schuhmann and A. Y. N.
Schouten-van Meeteren and E. Hoving and T. Brummer$^*$ and
C. M. van Tilburg$^*$ and S. M. Pfister$^*$ and O. Witt$^*$
and D. Jones$^*$ and K. Kerl and T. Milde$^*$},
title = {{MAPK} inhibitor sensitivity scores predict sensitivity
driven by the immune infiltration in pediatric low-grade
gliomas.},
journal = {Nature Communications},
volume = {14},
number = {1},
issn = {2041-1723},
address = {[London]},
publisher = {Nature Publishing Group UK},
reportid = {DKFZ-2023-01521},
pages = {4533},
year = {2023},
note = {#EA:B310#LA:B310#},
abstract = {Pediatric low-grade gliomas (pLGG) show heterogeneous
responses to MAPK inhibitors (MAPKi) in clinical trials.
Thus, more complex stratification biomarkers are needed to
identify patients likely to benefit from MAPKi therapy.
Here, we identify MAPK-related genes enriched in
MAPKi-sensitive cell lines using the GDSC dataset and apply
them to calculate class-specific MAPKi sensitivity scores
(MSSs) via single-sample gene set enrichment analysis. The
MSSs discriminate MAPKi-sensitive and non-sensitive cells in
the GDSC dataset and significantly correlate with response
to MAPKi in an independent PDX dataset. The MSSs discern
gliomas with varying MAPK alterations and are higher in pLGG
compared to other pediatric CNS tumors. Heterogenous MSSs
within pLGGs with the same MAPK alteration identify
proportions of potentially sensitive patients. The MEKi MSS
predicts treatment response in a small set of pLGG patients
treated with trametinib. High MSSs correlate with a higher
immune cell infiltration, with high expression in the
microglia compartment in single-cell RNA sequencing data,
while low MSSs correlate with low immune infiltration and
increased neuronal score. The MSSs represent predictive
tools for the stratification of pLGG patients and should be
prospectively validated in clinical trials. Our data
supports a role for microglia in the response to MAPKi.},
cin = {B310 / HD01 / C060 / B300 / FR01 / B062 / B360},
ddc = {500},
cid = {I:(DE-He78)B310-20160331 / I:(DE-He78)HD01-20160331 /
I:(DE-He78)C060-20160331 / I:(DE-He78)B300-20160331 /
I:(DE-He78)FR01-20160331 / I:(DE-He78)B062-20160331 /
I:(DE-He78)B360-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37500667},
doi = {10.1038/s41467-023-40235-8},
url = {https://inrepo02.dkfz.de/record/277810},
}